Amphetamine, Dextroamphetamine Mixed Salts Articles
Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR
14 February 2013
Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study
10 February 2013
Elan and Celgene settle over Abraxane; Watson re-challenges Shire Adderall XR patent
28 February 2011
Generic erosion will see ADHD drug market fall from $5 billion in 2009 to $4.1 billion in 2019
7 December 2010
Shire’s fourth-quarter 2009 earnings significantly beat expectations
22 February 2010
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
2 November 2009
Shire sales up 20% pre-Adderall demise
1 May 2009
Shire buys ADHD drugs from UCB
2 March 2009
US FDA swoops on YouTube "DTC abuse"
8 December 2008
Shire's HGT unveils ambitious growth plan, doubling sales contribution to 30% by 2015
1 December 2008
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
10 November 2008
Shire's Vyvanse projected to gain blockbuster status by 2017
13 October 2008
Shire ups forecast on strong 2nd qtr
11 August 2008
DEA block to US e-Rx adoption set to end
30 June 2008
Stock Commentary - New York week to May 26, 2008
2 June 2008
Shire: strong 1st qtr, wary over new drug
5 May 2008
Shire's Vyvanse cleared for ADHD in adults
28 April 2008
LB analysts: Shire is "heavily" over-valued
31 March 2008
Stock Commentary - Europe - week to Feb 4, 2008
11 February 2008
Barr's 3rd-qtr income falls 26% on Pliva costs
26 November 2007
Shire posts "best ever" results
12 November 2007
Barr's second-qtr 2007 profit halves to $45.3M
20 August 2007
Stock Commentary - Europe - week to July 9, 2007
16 July 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
Shire secures successor to Adderall XR as US FDA approves Vyvanse: another predicted blockbuster
5 March 2007
Shire's 2006 income hits $278M, sales up 16%
26 February 2007
SPD465 equivalent to Adderall XR plus MAS-IR in adult ADHD
27 November 2006
Shire's 3rd-qtr 2006 revenue rises 19%
6 November 2006
Andrx files ANDA for generic version of Shire's Adderall XR
9 October 2006
Study of ADHD drugs highlights functional differences
18 September 2006
ADD and ADHD
7 August 2006
Shire files SPD465 for adult ADHD
31 July 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
US FDA urged to warn on ADHD drugs
20 February 2006
Stock Commentary - Europe - week to Jan 23
30 January 2006
Shire and Impax settle Adderall dispute
30 January 2006
Adderall litigation update
30 January 2006
Stock Commentary - Europe - week to Aug 15
5 September 2005
UPDATE: Mixed reaction to Shire's $1.6B bid for TKT
27 April 2005
Shire will not sue Teva over Adderall generic
25 April 2005
Upbeat forecast from Shire Pharma
11 April 2005
Shire announces 13% growth in revenue
7 March 2005
Stock Commentary - Europe
28 February 2005
Teva files for generic Adderall in USA
28 February 2005
Stock Commentary - Europe
21 February 2005
Shire's Adderall withdrawn in Canada
14 February 2005
Shire update on generic Adderall cases
24 January 2005
Lilly adds liver warning to Strattera label
10 January 2005
Shire granted extension for Adderall XR by FDA
8 November 2004
Stock Commentary - Europe
23 August 2004
FDA OKs Adderall XR for ADHD in adults
23 August 2004
Shire raises forecasts on good 2nd-qtr
9 August 2004
Strong performace for Shire in 2003
22 March 2004
Shire's Adderall XR available in Canada
9 February 2004
Stock Commentary - Europe
5 January 2004
Shire files suit against IMPAX
5 January 2004
Shire's Adderall XR facing further generic comp
24 November 2003
Shire beats expectations in third quarter as ADHD product sales soar
17 November 2003
Adderall XR on track for US use in adults
27 October 2003
Eli Lilly's Strattera gains 16.3% of new Rxs in the USA
27 October 2003
Shire files key law suit against Barr Labs
8 September 2003
Stock Commentary - Europe
12 May 2003
Adderall drives growth at Shire in 1st quarter
12 May 2003
Barr's generic Adderall cleared in USA
31 March 2003
Shire's profits up on switching strategy
3 March 2003
Shire gets tough in Adderall XR defense
3 March 2003
Shire hit by Adderall XR patent challenge
13 January 2003
Shire
12 August 2002
Ranbaxy gets OK for generic Adderall
1 July 2002
Eon gets OK for 2nd generic of Adderall
24 June 2002
Shire's Fosrenol clears bone safety hurdle
17 June 2002
Novartis' Ritalin LA cleared in USA
17 June 2002
Novartis' Ritalin LA cleared in USA
17 June 2002
Generic success sparks further competition
20 May 2002
Barr Labs being sued by Organon, Shire
13 May 2002
Revenues in 1st-qtr rise 30% at Shire
6 May 2002
Stock Commentary - Europe
11 March 2002
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
